May 2010, Vol 1, No 1

Barcelona—An effort to monitor and modify prescription drug use in breast cancer patients prescribed tamoxifen can help prevent the polypharmacy that lessens tamoxifen’s effectiveness.

Barcelona—For women with the BRCA1 or 2 genetic mutation that predisposes them to breast cancer, the option to undergo prophylactic mastectomy of the other, noncancerous breast following their initial breast cancer treatment does not improve disease-free survival or overall survival, said researchers at the EBCC7 meeting.

San Francisco, CA—By mining the Surveillance, Epidemiology and End Results-Medicare Database, researchers have documented a significant de cline in nonevidence-based use of androgen deprivation therapy (ADT) for prostate cancer between 2003 and 2005.

San Francisco, CA—A new study challenges the notion that more testing leads to greater accuracy in detection of non–muscle-invasive bladder cancer (NMIBC).

San Francisco, CA—The expression “a picture is worth a thousand words” is certainly true when it comes to figures from a new literature review of prostate cancer (PCa) treatments.

Hollywood, FL—As specialty pharmacy (SP) expands rapidly into oncology, there is a need to better define its role. This was the aim of the National Comprehensive Cancer Network (NCCN) Task Force on Specialty Pharmacy, whose chair presented the group’s preliminary report at the 15th Annual NCCN Conference.